Modular Medical Announces Addition to the Russell Microcap(R) Index
Modular Medical Announces Addition to the Russell Microcap(R) Index
SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024.
医疗模块化公司（Modular Medical，纳斯达克：MODD），一个处于开发阶段的胰岛素输送技术公司，旨在推出下一代用户友好，价格实惠的胰岛素泵技术。今天宣布，它将在 2024 年 Russell 指数年度重新编制结束时成为 Russell 微小市值指数的成员，并于 2024 年 7 月 1 日美国市场开盘时生效。
Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
成为 Russell 微小市值指数成员，意味着一年内自动纳入适当的成长风格指数和价值风格指数。FTSE Russell 主要根据客观的市值排名和风格属性确定其 Russell 指数的成员。
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.
Russell 指数被投资经理和机构投资者广泛用于指数基金和作为主动投资策略的基准。大约有 10.6 万亿美元的资产以 Russell 的美国指数为基准。Russell 指数是全球领先的指数提供商 FTSE Russell 的一部分。
For more information on the Russell Microcap Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.
有关 Russell 微小市值指数和 Russell 指数重新编制的更多信息，请访问 FTSE Russell 网站上的“Russell Reconstitution”部分。
About Modular Medical
关于医疗模块化公司
Modular Medical, Inc. (Nasdaq: MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."
医疗模块化公司（纳斯达克：MODD）是一家处于开发阶段的医疗器械公司，计划推出下一代胰岛素输送技术。公司使用其专利技术，力求消除复杂性与功效之间的权衡，从而使高质量的胰岛素输送既负担得起又容易学习。我们的使命是提高糖尿病患者获得最高标准的血糖控制的机会，超越“超级用户”，为“我们其他人”的糖尿病护理提供支持。
Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at
医疗模块化公司由经验丰富的医疗设备专业人士和微流控工程师保罗·迪佩纳于成立。在创立医疗模块化公司之前，迪佩纳先生是 Tandem Diabetes 的创始人（2005 年），发明和设计了其 t：slim 胰岛素泵。更多信息可在
All trademarks mentioned herein are the property of their respective owners.
这里提到的所有商标均为其各自所有者的财产。
CONTACT:
联系人：
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com
Jeb Besser
首席执行官
医疗模块化公司
+1 (617) 399-1741
IR@modular-medical.com
SOURCE: Modular Medical, Inc.
来源：Modular Medical, Inc。